Abstract
Recent evidence suggests that the vasopressin analogue desglycinamide-arginine8-vasopressin (DGAVP) might specifically benefit mild brain trauma patients. We investigated the effect of intranasal DGAVP treatment in 32 patients who had sustained a mild head injury for 3 months in a double-blind, placebo-controlled, matched-pairs study. DGAVP did not have a positive effect on cognitive recovery in this group of mildly affected patients.
| Original language | English |
|---|---|
| Pages (from-to) | 103-106 |
| Number of pages | 4 |
| Journal | Neurology |
| Volume | 43 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - 1 Jan 1993 |
Fingerprint
Dive into the research topics of 'A controlled trial with vasopressin analogue (DGAW) on cognitive recovery immediately after head trauma'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver